KRAS and colorectal carcinoma: In the case of CRC, the best characterized is BI-1701963, which is under clinical evaluation for metastatic CRC patients with mutant KRAS (https://clinicaltrials.gov/ct2/show/NCT04627142 accessed on 10 May 2021).